Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of dinutuximab beta. All patients received standard ind...

Full description

Bibliographic Details
Main Authors: Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Shifra Ash, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck-Popovic, Guenter Schreier, Hans Loibner, Peter Ambros, Keith Holmes, Maria Rita Castellani, Mark N. Gaze, Alberto Garaventa, Andrew D.J. Pearson, Holger N. Lode
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
high-risk neuroblastoma
immunotherapy
dinutuximab beta
Online Access:https://www.mdpi.com/2072-6694/12/2/309

Internet

https://www.mdpi.com/2072-6694/12/2/309

Similar Items